RhyGaze

Executive Summary

RhyGaze is a Swiss biotechnology company founded in 2021, dedicated to restoring vision in patients with blindness caused by loss of light-converting cells in the retina. Leveraging advances in genetics, the company aims to reproduce essential components of the eye's visual system, enabling the conversion of light into electrical signals that the brain can interpret. With a focus on gene therapy, RhyGaze's approach addresses a significant unmet need in ophthalmology, targeting conditions such as retinitis pigmentosa and age-related macular degeneration, where current treatments are limited. Headquartered in Zurich, the company is privately held and operates in the RNA & Gene Therapy sector, with no disclosed funding or valuation to date. While detailed pipeline information is not publicly available, RhyGaze's mission and technological platform position it as an early-stage innovator in the ocular gene therapy space, potentially attracting interest from investors and partners seeking novel treatments for vision loss.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate IND-Enabling Studies Initiation50% success
• Q4 2026Series A Financing Round60% success
• Q1 2027Research Collaboration or Licensing Deal40% success